Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2018American Journal of HematologyOpen Access

Transitioning patients with immune thrombocytopenia to second‐line therapy: Challenges and best practices

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAdam CukerBrigham and Women's Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Adam Cuker (2018) studied this question.

synapsesocial.com/papers/6a75e6957d7eb453cc70730fhttps://doi.org/10.1002/ajh.25092
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hematological Problems in Pediatric Intensive Care2013 · 3,516 citations
  2. 2Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome.1995 · 102 citations
  3. 3Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy2013 · 274 citations
  4. 4Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia2009 · 201 citations